Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct;74(16):1973-1981.
doi: 10.1007/s40265-014-0314-5.

Pembrolizumab: first global approval

Raewyn M Poole  1
Affiliations
Review

Pembrolizumab: first global approval

Raewyn M Poole. Drugs. 2014 Oct.

Abstract

Pembrolizumab [Keytruda(®) (US)], a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein, has been developed by Merck & Co for the treatment of cancer. Pembrolizumab has received its first global approval for the treatment of advanced, unresectable or metastatic malignant melanoma in the US, for use in patients with disease progression after prior treatment with ipilimumab and, for BRAF V600 mutation-positive patients, a BRAF inhibitor. It is the first anti-PD-1 therapy to receive regulatory approval in the US, and is currently under regulatory review in the EU. This article summarizes the milestones in the development of pembrolizumab leading to this first approval for the treatment of malignant melanoma.

PubMed Disclaimer

References

    1. Lancet. 2014 Sep 20;384(9948):1109-17 - PubMed
    1. Arch Dermatol Res. 2014 Aug;306(6):511-9 - PubMed
    1. Am J Clin Dermatol. 2014 Aug;15(4):323-37 - PubMed
    1. Curr Treat Options Oncol. 2014 Dec;15(4):658-69 - PubMed
    1. Clin Cancer Res. 2013 Mar 1;19(5):1009-20 - PubMed

MeSH terms